Key Information
Source
summary/abstract
The standard of care for wild-type ATTR amyloidosis (wtATTR) centers on TTR stabilizers like tafamidis, which slow disease progression. Patients must carefully manage symptoms with diuretics and often need to avoid standard heart medications like beta-blockers that can worsen fatigue.
Treating wild-type transthyretin amyloidosis (wtATTR) has evolved from simply managing symptoms to using “disease-modifying” therapies that target the underlying protein problem. Because your heart is thick and stiff (restrictive), it responds differently to medications than a “typical” heart failure patient might